Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors.

Chien-Chang KaoChing-Liang HoMing-Hsin YangYi-Ta TsaiShu-Yu LiuPing-Ying ChangYi-Ying WuJia-Hong ChenTzu-Chuan HuangRen-Hua YehnMing-Shen DaiYeu-Chin ChenGuang-Huan SunTai-Lung Cha

Published in: Journal of clinical medicine (2022)

Co-administration therapy of GW5074 and sorafenib demonstrated a favorable safety profile and showed anti-tumor activity in a variety of tumor types. However, the solubility of GW5074 is not satisfactory. A future phase 2a trial will be carried out using the new salted form that has been proven to be more effective.

Keyphrases

phase iii
study protocol
phase ii
clinical trial
cancer therapy
open label
current status
stem cells
drug delivery
bone marrow
replacement therapy